FDA Inspection Readiness
Regulated manufacturers may be subject to multiple FDA requirements. Manufacturers covered by the medical-device Quality Management System Regulation must comply with applicable requirements of 21 CFR Part 820, which incorporates ISO 13485:2016. Manufacturers of finished pharmaceutical products generally must comply with applicable drug CGMP requirements in 21 CFR Parts 210 and 211. FDA-regulated electronic records and electronic signatures may also be subject to 21 CFR Part 11 when they fall within its scope.
These requirements address related quality-system activities but are not interchangeable. Part 820 establishes broad quality-management requirements for finished medical devices, including applicable design-and-development controls, while Parts 210 and 211 establish manufacturing and quality controls intended to assure the safety, identity, strength, quality, and purity of drugs.
Drug-device combination products are subject to the framework in 21 CFR Part 4. Depending on the product and manufacturing arrangement, applicable drug and device CGMP requirements may be satisfied through a comprehensive or permitted streamlined operating system. Part 11 applies separately when regulated records or signatures are maintained, relied upon, or submitted electronically within its scope.
Effective inspection-readiness activities help identify applicable requirements, operational overlaps, and potential gaps while maintaining clear regulatory accountability.
Continuous FDA Inspection Readiness Program
Maintaining readiness for an FDA inspection is supported by ongoing oversight of quality systems, manufacturing operations, and associated records. Quality and regulatory teams may encounter questions concerning inspection expectations, deviation and complaint investigations, corrective and preventive actions, documentation practices, and the application of FDA requirements.
Organizations may not always have immediate access to professionals with relevant FDA inspection and compliance experience. Our advisory team includes former FDA investigators and compliance personnel, together with former regulatory reviewers, who bring experience evaluating manufacturing operations, quality systems, compliance matters, and regulatory submissions.
The Continuous FDA Inspection Readiness Program provides manufacturers with ongoing advisory support to identify potential gaps, address regulatory questions, and strengthen inspection readiness between inspections.
Disclaimer: This is an independent advisory service and is not affiliated with or endorsed by the U.S. Food and Drug Administration. Participation does not guarantee regulatory compliance or any particular inspection outcome.
Do Your Quality and Regulatory Teams Have Access to Inspection-Informed Experience?
Quality and regulatory teams play important roles in supporting compliant quality systems and preparing for regulatory inspections. Complex questions may arise concerning the application of FDA requirements, the adequacy of investigations and corrective actions, documentation practices, and how manufacturing operations and quality systems may be evaluated during an inspection.
Access to experienced regulatory advisors can help organizations identify potential compliance gaps and strengthen inspection readiness before an inspection begins.
Flexible Access to Specialized Regulatory Experience
Maintaining full-time personnel with substantial FDA inspection and compliance experience may not fit every organization’s staffing model or business needs. Some manufacturers may require this specialized experience only at particular stages or when significant regulatory questions arise.
The Continuous FDA Inspection Readiness Program offers an alternative by providing ongoing access to advisors who include former FDA investigators and compliance personnel, together with former regulatory reviewers. These professionals bring experience from different aspects of FDA inspection, compliance, and regulatory-review activities.
This advisory model supplements—not replaces—the manufacturer’s responsibility for its quality system, regulatory decisions, and compliance.
Access to Experienced Regulatory Advisors
Subject to the program’s service terms, participants may obtain advisory support through several communication channels.
- Remote Consultation. Regulatory discussions are conducted through video meetings or telephone consultations.
- Email Advisory Support. Written guidance concerning regulatory questions and quality-system considerations.
- Strategic Advisory Meetings. Periodic discussions with quality and leadership teams concerning compliance priorities and inspection readiness.
- Inspection-Readiness Activities. Preparation discussions and, when appropriate, mock-inspection exercises are designed to evaluate readiness and identify potential gaps.
- Continuous Inspection Readiness. FDA inspections may examine historical records, investigations, quality-system practices, and ongoing manufacturing operations. Regular review of these areas can help manufacturers identify potential compliance risks and strengthen quality-system oversight.
The Continuous FDA Inspection Readiness Program provides ongoing advisory support designed to help manufacturers prepare for regulatory inspections and maintain readiness between inspections.
The Complexity of Combination Product Compliance
Combination products can be subject to overlapping FDA requirements because they contain two or more regulated constituent parts—drug, device, or biological product—or involve separately distributed products intended for use together.
21 CFR Part 3 addresses product classification and FDA-center assignment, while 21 CFR Part 4 establishes requirements for combination-product manufacturing and postmarketing safety reporting. Depending on the constituent parts, applicable requirements may also include the drug CGMP regulations in 21 CFR Parts 210 and 211, the medical-device Quality Management System Regulation in 21 CFR Part 820, and requirements governing biological products or human cells and tissues.
For certain single-entity and co-packaged products, Part 4 permits a streamlined CGMP operating system. Manufacturers must nevertheless identify and satisfy all applicable requirements for each constituent part.
Failure to comply may result in inspectional observations documented on Form FDA 483 and, depending on the nature and significance of the findings, warning letters, import detention or refusal, recalls, or other regulatory action. A Form FDA 483 documents an investigator’s observations and is not itself a final FDA determination of noncompliance.
Because the applicable framework depends on the product, constituent parts, manufacturing arrangement, and records involved, an inspection-readiness assessment and regulatory gap analysis can help identify potential compliance gaps before an inspection or regulatory assessment begins.
21 CFR Part 820: QMSR and ISO 13485:2016
Effective February 2, 2026, the FDA’s former Quality System Regulation was replaced by the Quality Management System Regulation under 21 CFR Part 820. The QMSR incorporates ISO 13485:2016 by reference and supplements it with FDA-specific definitions and requirements.
This framework aligns U.S. medical-device quality-management requirements more closely with those used by other regulatory authorities. The alignment is intended to promote regulatory consistency and may reduce duplication for manufacturers operating internationally while maintaining the FDA’s requirements for the safety and effectiveness of finished medical devices.
Compliance involves more than updating terminology. Manufacturers must apply the incorporated ISO 13485 requirements together with the supplemental provisions in Part 820, the Federal Food, Drug, and Cosmetic Act, and other applicable FDA regulations. ISO 13485 certification by itself does not establish full compliance with the QMSR.
A structured gap assessment can help a manufacturer evaluate its existing quality management system against the current framework, identify potential deficiencies, and prioritize necessary corrective actions. The table below compares key elements of the former Quality System Regulation with the corresponding QMSR and ISO 13485:2016 requirements.
Our Services
The Role of Gap Analysis in Risk Reduction
Combination-product quality and compliance risks may have patient-safety, regulatory, financial, and reputational consequences. Serious product failures or significant compliance deficiencies may contribute to recalls, warning letters, import actions, injunctions, or other regulatory measures. A structured gap assessment can help identify weaknesses before an FDA inspection or regulatory assessment begins. The assessment should compare the manufacturer’s quality system, manufacturing operations, and records with the requirements applicable to the product and its constituent parts.
Depending on the product and manufacturing arrangement, the review may address drug CGMP requirements in 21 CFR Parts 210 and 211, the Quality Management System Regulation in 21 CFR Part 820, the ISO 13485:2016 requirements incorporated by reference, and the combination-product framework in 21 CFR Part 4.
Areas of review may include design-and-development documentation, the medical device file, legacy DHF or DMR records where relevant, batch records, facilities and equipment, process validation, personnel training, supplier controls, complaints, investigations, and corrective and preventive actions. A useful assessment does more than identify potential deficiencies. It prioritizes findings according to applicable requirements and product risk and provides a practical remediation plan. Inspection-readiness work can strengthen a manufacturer’s ability to demonstrate that its systems are appropriately controlled, but it cannot guarantee a particular inspection classification or outcome.
The Value of Relevant FDA Inspection Experience
Former FDA investigators can provide a valuable perspective based on experience conducting inspections and evaluating regulated manufacturing operations. When that experience is current and relevant to the product type, it can inform assessments of documentation, investigations, supplier controls, manufacturing processes, and inspection readiness.
Former FDA experience is not the only qualification that matters. Effective advisors should also demonstrate current knowledge of 21 CFR Part 4, drug CGMP requirements, the QMSR, and ISO 13485:2016, together with relevant manufacturing, quality-system, remediation, and combination-product experience.
Advisors should base their recommendations on current laws, regulations, FDA guidance and policy, product risk, and documented professional experience. Their work should supplement—not replace—the manufacturer’s responsibility for its quality system and regulatory compliance.
No Room for Error
Combination-product compliance is not something to improvise. Depending on the product and its constituent parts, manufacturers may need to address the combination-product framework in 21 CFR Part 4, drug CGMP requirements in Parts 210 and 211, and the Quality Management System Regulation in Part 820. Effective compliance requires precision, clarity, and relevant experience.
A well-designed inspection-readiness program can help identify potential gaps, prioritize risks, and align quality systems and manufacturing operations with applicable FDA requirements. A structured gap assessment provides a practical starting point, but identified deficiencies must be followed by appropriate corrective actions and effectiveness checks.
Regulatory advisors should be selected based on relevant combination-product, manufacturing, quality-system, inspection, and remediation experience. Former FDA inspection experience can provide valuable perspective, but no consultant can guarantee an inspection outcome or know exactly how FDA will act in a particular matter. Responsibility for the quality system and regulatory compliance remains with the manufacturer.
When patient safety, product quality, and regulatory compliance are at stake, there is no room for error.